ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP33-25 Commercial Pharmacy Benefit Exclusion for Bkemv™, Otulfi™, Pyzchiva®, Selarsdi™ and Ustekinumab-ttwe™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 09, 2025
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 3131 - 3140 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP32-25 Cotiviti to Begin Preventable Readmission Audits
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 09, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP31-25 Peer-to-Peer Discussions for Denied Claims Ending
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါအ့ဖြ့ၣ် 09, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2025 May Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 01, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P30-25 Prime Therapeutics Management (UM) Program: Medical Drug Updates
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါမ့ၤ 01, 2025